Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naive Patients with Moderate-to-Severe Ulcerative Colitis in Japan.

ABSTRACT:

Objective

Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC). The objective of this study was to evaluate the long-term cost-effectiveness of tofacitinib versus current biologics, considering combinations of first-line (1L) and second-line (2L) therapies, from a Japanese payer's perspective in patients with moderate-to-severe active UC following an inadequate response to conventional therapy and in those who were naïve to biologics.

Methods

A cost-effectiveness analysis was conducted during the time horizon specified in the Markov model, which considers a patient's lifetime as 60 years and an annual discount rate of 2% on costs and effects. The model compared tofacitinib with vedolizumab, infliximab, adalimumab, golimumab, and

SUBMITTER: Kobayashi T 

PROVIDER: S-EPMC10085930 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature